首页> 外文期刊>British journal of clinical pharmacology >Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes
【24h】

Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes

机译:减肥手术后口服药物生物利用度的趋势:检查对不同药物类别暴露影响的变化程度

获取原文
获取外文期刊封面目录资料

摘要

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT? Changes to oral drug bioavailability have been observed post bariatric surgery. However, the magnitude and the direction of changes have not been assessed systematically to provide insights into the parameters governing the observed trends. Understanding these can help with dose adjustments.WHAT THIS STUDY ADDS? Analysis of drug characteristics based on a biopharmaceutical classification system is not adequate to explain observed trends in altered oral drug bioavailability following bariatric surgery, although the findings suggest solubility to play an important role.AIMSTo identify the most commonly prescribed drugs in a bariatric surgery population and to assess existing evidence regarding trends in oral drug bioavailability post bariatric surgery.METHODSA retrospective audit was undertaken to document commonly prescribed drugs amongst patients undergoing bariatric surgery in an NHS hospital in the UK and to assess practice for drug administration following bariatric surgery. The available literature was examined for trends relating to drug permeability and solubility with regards to the Biopharmaceutics Classification System (BCS) and main route of elimination.RESULTSNo significant difference in the ‘post/pre surgery oral drug exposure ratio’ (ppR) was apparent between BCS class I to IV drugs, with regards to dose number (Do) or main route of elimination. Drugs classified as ‘solubility limited’ displayed an overall reduction as compared with ‘freely soluble’ compounds, as well as an unaltered and increased ppR.CONCLUSIONClinical studies establishing guidelines for commonly prescribed drugs, and the monitoring of drugs exhibiting a narrow therapeutic window or without a readily assessed clinical endpoint, are warranted. Using mechanistically based pharmacokinetic modelling for simulating the multivariate nature of changes in drug exposure may serve as a useful tool in the further understanding of postoperative trends in oral drug exposure and in developing practical clinical guidance.
机译:此主题已经知道什么?减肥手术后已观察到口服药物生物利用度的变化。但是,尚未对系统的变化幅度和方向进行系统评估,以了解控制观测趋势的参数。了解这些可以帮助调整剂量。尽管基于生物药物分类系统的药物特性分析不足以解释肥胖症手术后观察到的口服药物生物利用度变化的趋势,但研究结果表明溶解度起着重要作用。为了评估减肥手术后口服药物生物利用度趋势的现有证据,METHODSA进行了追溯审核,以记录在英国NHS医院进行减肥手术的患者中常用处方药的记录,并评估减肥手术后的药物管理实践。审查了现有文献中有关生物药物分类系统(BCS)和主要消除途径的与药物渗透性和溶解度有关的趋势。结果在``术后/术前口服药物接触率''(ppR)之间无明显差异BCS I至IV类药物,关于剂量数(Do)或消除的主要途径。与“易溶”化合物相比,归类为“溶解度受限”的药物显示出总体降低,并且ppR不变且升高。结论结论临床研究建立了常用处方药的指南,并且监测显示治疗窗狭窄或不存在的药物易于评估的临床终点是必要的。使用基于机理的药代动力学模型来模拟药物暴露变化的多变量性质,可以作为进一步了解口服药物暴露术后趋势和开发实用临床指南的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号